Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
Clears major obesity endpoints at 80 weeks
Subscribe To Our Newsletter & Stay Updated
